Your browser is no longer supported. Please, upgrade your browser.
FLXN Flexion Therapeutics, Inc. monthly Stock Chart
Flexion Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.09 Insider Own1.90% Shs Outstand49.30M Perf Week-2.43%
Market Cap534.62M Forward P/E- EPS next Y-1.62 Insider Trans0.00% Shs Float46.24M Perf Month-9.30%
Income-127.60M PEG- EPS next Q-0.45 Inst Own- Short Float22.51% Perf Quarter-5.83%
Sales82.90M P/S6.45 EPS this Y12.50% Inst Trans2.21% Short Ratio19.38 Perf Half Y-4.84%
Book/sh-0.06 P/B- EPS next Y38.40% ROA-53.30% Target Price- Perf Year-39.59%
Cash/sh3.75 P/C2.89 EPS next 5Y20.00% ROE865.00% 52W Range5.01 - 22.98 Perf YTD-47.73%
Dividend- P/FCF- EPS past 5Y-14.90% ROI-78.50% 52W High-52.92% Beta1.63
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin79.70% 52W Low115.97% ATR0.66
Employees288 Current Ratio4.70 Sales Q/Q8.70% Oper. Margin- RSI (14)43.69 Volatility5.15% 6.05%
OptionableYes Debt/Eq- EPS Q/Q50.20% Profit Margin- Rel Volume0.58 Prev Close10.84
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume537.27K Price10.82
Recom1.80 SMA20-7.11% SMA50-6.66% SMA200-6.24% Volume311,966 Change-0.18%
Aug-20-20Initiated Goldman Neutral $15
Jul-31-20Initiated Oppenheimer Outperform $19
Jul-29-20Initiated Credit Suisse Outperform $19
Jun-25-20Initiated H.C. Wainwright Buy $25
May-27-20Initiated Guggenheim Buy $20
Dec-27-19Reiterated The Benchmark Company Buy $19 → $25
Dec-05-19Initiated Craig Hallum Buy
Nov-25-19Initiated BTIG Research Buy $27
May-09-19Upgrade The Benchmark Company Hold → Buy $19
Jan-04-19Reiterated Needham Buy $42 → $36
Jan-04-19Downgrade The Benchmark Company Buy → Hold
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
Nov-06-20 04:30PM  
Nov-05-20 04:30PM  
Nov-04-20 06:15PM  
Nov-02-20 11:28AM  
Oct-29-20 04:30PM  
Oct-13-20 06:59AM  
Oct-08-20 04:30PM  
Oct-05-20 09:00AM  
Oct-02-20 04:30PM  
Sep-21-20 08:37AM  
Sep-09-20 04:30PM  
Sep-08-20 04:30PM  
Sep-04-20 04:30PM  
Sep-03-20 04:30PM  
Aug-20-20 09:51AM  
Aug-19-20 09:00AM  
Aug-07-20 04:30PM  
Aug-06-20 12:27PM  
Aug-05-20 07:05PM  
Jul-30-20 04:30PM  
Jul-28-20 12:32PM  
Jul-24-20 06:31AM  
Jul-23-20 12:00PM  
Jul-15-20 09:56AM  
Jul-14-20 06:59AM  
Jul-08-20 12:00PM  
Jul-02-20 08:30AM  
Jun-27-20 01:20PM  
Jun-25-20 10:10AM  
Jun-16-20 04:30PM  
Jun-11-20 05:36PM  
May-28-20 09:13AM  
May-21-20 12:02PM  
May-20-20 04:01PM  
May-14-20 09:27AM  
May-13-20 05:00PM  
May-09-20 03:00PM  
May-07-20 04:01PM  
May-05-20 09:00AM  
May-01-20 09:00AM  
Apr-30-20 04:30PM  
Apr-27-20 07:30AM  
Apr-07-20 04:30PM  
Apr-03-20 04:30PM  
Apr-01-20 07:00AM  
Mar-16-20 03:49PM  
Mar-14-20 08:55AM  
Mar-12-20 06:35PM  
Mar-11-20 04:30PM  
Mar-06-20 04:30PM  
Mar-05-20 12:30PM  
Mar-04-20 04:30PM  
Feb-24-20 04:30PM  
Feb-20-20 12:31PM  
Feb-07-20 04:30PM  
Jan-28-20 02:36PM  
Jan-15-20 06:34AM  
Jan-13-20 08:30AM  
Jan-10-20 07:13AM  
Jan-09-20 04:01PM  
Jan-03-20 04:30PM  
Jan-01-20 06:00PM  
Dec-31-19 09:39AM  
Dec-30-19 09:44AM  
Dec-27-19 04:36PM  
Dec-26-19 04:15PM  
Dec-17-19 07:30AM  
Dec-12-19 03:42PM  
Dec-10-19 09:00AM  
Dec-09-19 09:00AM  
Dec-06-19 04:30PM  
Nov-17-19 07:14AM  
Nov-11-19 07:30AM  
Nov-07-19 07:15PM  
Nov-04-19 07:48AM  
Nov-01-19 04:40PM  
Oct-31-19 04:30PM  
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILINAZZO ALANDirectorJul 09Option Exercise2.2018,45040,50022,950Jul 10 04:06 PM
Stejbach MarkDirectorMay 26Buy9.752,05119,9972,051May 27 04:14 PM
Clayman Michael D.President and CEOMay 26Buy9.7510,25699,996346,605May 27 04:11 PM
Arkowitz DavidChief Financial OfficerMay 07Sale10.882,41326,253117,068May 11 04:11 PM